Vivek Subbiah
University of Texas MD Anderson Cancer Center
CancerInternal medicinePathologyOncologyAdverse effectLung cancerChemotherapyMelanomaImmunotherapySarcomaTargeted therapyIn patientPhases of clinical researchCancer researchClinical trialBioinformaticsMedicinePI3K/AKT/mTOR pathwayBiologyPharmacology
590Publications
55H-index
7,858Citations
Publications 620
Newest
#2Eric X. ChenH-Index: 3
Last. Daniel J. RenoufH-Index: 27
view all 19 authors...
Source
#1Amita PatnaikH-Index: 77
#2Vivek SubbiahH-Index: 55
Last. Edward ChaH-Index: 19
view all 12 authors...
Source
#1Sreeram V Ramagopalan (Hoffmann-La Roche)H-Index: 1
#2Alind Gupta (Cytel)H-Index: 1
Last. Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
view all 6 authors...
Importance null Evidence regarding real-world effectiveness of therapies for patients with advanced non-small cell lung cancer (NSCLC) whose tumors are resistant to platinum-based chemotherapy is lacking. null Objective null To compare the effectiveness of the immune checkpoint inhibitors atezolizumab (programmed cell death ligand 1 inhibitor) and nivolumab (programmed cell death 1 inhibitor) and the chemotherapy drug docetaxel in patients with advanced NSCLC resistant to platinum-based chemothe...
Source
Source
Source
Source
#1Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Source
#1Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Drug delivery to select therapeutic targets for precision oncology has always been a major challenge in oncology. Anti-body drug conjugates (ADC) and radiopharmaceuticals attempt to overcome the major limitations of chemotherapy or mono-clonal antibody therapy as they provide a highly specific means of attacking the vulnerability of the cancer cell. Currently there are over 100 clinical trials in various stages of development with these agents. Years of improved understanding of ADC technology a...
Source
#1Jason Roszik (University of Texas MD Anderson Cancer Center)H-Index: 34
#2Lisa Maria Mustachio (University of Texas MD Anderson Cancer Center)H-Index: 10
Last. Anthony Paul Conley (University of Texas MD Anderson Cancer Center)H-Index: 20
view all 7 authors...
Soft tissue sarcomas, depending on the subtype and grade, frequently recur and become metastatic after localized treatment. There is now great interest in applying immunotherapy to sarcomas to immuno-profile the different subtypes and immune monitor for prognosis. Our group previously showed that key immunotherapy target genes are present in sarcomas. Here, we extend our findings by demonstrating that sarcomas with a relatively high mutational load are likely to be more sensitive to immunotherap...
Source
#1Roberto Carmagnani Pestana (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Jason Roszik (University of Texas MD Anderson Cancer Center)H-Index: 34
Last. Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
view all 7 authors...
Recent failure of phase 3 trials and paucity of druggable oncogenic drivers hamper developmental therapeutics in sarcomas. Antibody-based therapeutics, like antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR)-based therapeutics, have emerged as promising strategies for anticancer drug delivery. The efficacy of these novel therapies is highly dependent on expression of the antibody target. We used RNA sequencing data from Cancer Genome Atlas (TCGA) to analyze expression of target ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.